-
Frontiers of Research Data from China! Correlation between TFF1 gene polymorphisms and kidney stone risk
Time of Update: 2022-09-07
Research resultsThe results of a case-control study of the two-phase design showed a significant increased risk of kidney stones in individuals with rs3761376 A alleles (AA and AG) compared with the GG genotype [corrected odds ratio (OR) = 1.
-
【Neo Desecretion】Separation and Combination: Case Analysis of Complete Remission of cT2b Bladder Cancer After Neoadjuvant Immunocombination Chemotherapy
Time of Update: 2022-08-20
Figure 3 MR of the patient in July 2021Analysis after 4 cycles of neoadjuvant therapy: The pathological grade of the patient was low-grade urothelial carcinoma, but the stage was determined to be muscle invasive, which may be related to the long medical history, so the existing lymph node micrometastases cannot be ruled out .
-
【Science Sub-Journal】Single-cell sequencing for male infertility—optimizing circular sperm cell injection technology
Time of Update: 2022-08-20
This article is original from Translational Medicine Network, please indicate the source for reprinting Author: kopeIntroduction: Azoospermia is the main cause of male infertility, and its incidence i
-
Specialized in protecting the bladder: BTARS
Time of Update: 2022-08-15
Research and development of super mirrors (S mirrors) Introduction Yimaitong Department of Urology reported on June 2, 2017 that "the new bladder cancer surgery proposed by Chinese scholars won the Best Poster Award at the 2017 AUA Annual Meeting in the United States".
-
7+ single-cell pyroptosis, still worth digging
Time of Update: 2022-08-15
. Results The genomic and transcriptomic landscape of pyroptosis-related regulators in muscle-invasive bladder cancer was based on significant differences in the expression of pyroptotic genes between different molecular subtypes of bladder cancer TCGA (Fig. 1A), as shown by the protein-protein interaction network.
-
Frontier Progress TITAN Study Japanese Subgroup Final Results Released
Time of Update: 2022-06-20
The TITAN study is a randomized, double-blind, placebo-controlled, multinational trial to evaluate the efficacy of apalutamide plus androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer (mCSPC) .
-
NEJM: Oral drug for complicated urinary tract infection, efficacy is non-inferior to intravenous drip expert review
Time of Update: 2022-06-19
This phase 3 clinical trial, conducted in 95 hospitals worldwide, aims to demonstrate that tipipenem hydrobromide is noninferior to ertapenem in the treatment of complex UTIs, including acute pyelonephritis, with a non-inferiority margin The value of 12.
-
HOKUTO Study Mirabegron Significantly Improves Overactive Bladder Symptoms in Frail Patients Over 80
Time of Update: 2022-06-19
The end point of the study was after 4, 8, and 12 weeks of treatment, and the changes from baseline in the following items were compared: OABSS, International Prostate Symptom Scale (IPSS) score, IPSS QOL score, OAB questionnaire score, urine flow measurement (UFM) results, residual Urinalysis (PVR), Frail Elderly Screening Scale (VES-13) score, Mini-Mental State Examination (MMSE) score .
-
Immunotherapy showed miraculous effects, advanced bladder cancer combined with uremia, the lesions completely disappeared!
Time of Update: 2022-06-19
Urothelial carcinoma At present, systemic chemotherapy is the first-line standard treatment to inhibit the further progression of metastatic bladder cancer, but its efficacy is not satisfactory.
This suggests that immune checkpoint inhibitors have potential for second-line treatment of urothelial cancer patients with end-stage renal disease and long-term dialysis .
-
Interpretation of the 2022 Guidelines for Prostate Cancer Screening, Early Diagnosis and Treatment in China (Part 2)
Time of Update: 2022-06-19
Regarding other screening methods, the "Clinical Application of Prostate-Specific Antigen Detection for Prostate Cancer" issued by the National Health and Family Planning Commission in 2015 pointed out that when the serum PSA concentration is ≥4.
-
AACR treatment of bladder cancer, bicyclic peptide conjugate therapy achieves 50% objective response rate
Time of Update: 2022-06-18
▲Characteristic comparison of bicyclic peptides with small molecules and antibodies (Image source: Bicycle Therapeutics' official website) In this clinical trial, patients with solid tumors who had received an average of 3 previous treatments received different doses of BT8009, of which 49% for urothelial carcinoma patients .
-
2022 AACR Breaking With Tradition?
Time of Update: 2022-06-18
Let's take a look at updated data from a phase II trial of adaptive abiraterone guided by mathematical modeling in metastatic castration-resistant prostate cancer (mCRPC) .
We applied this model to guide whether to start or end a treatment cycle with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) .
-
Encouraging results from 2022 AACR maveropepimut-S, intermittent low-dose cyclophosphamide combined with pembrolizumab in advanced, metastatic bladder cancer
Time of Update: 2022-06-17
Safety, preliminary efficacy, and efficacy of the combination of maveropepimut-S (MVP-S), intermittent low-dose cyclophosphamide, and pembrolizumab in patients with advanced, metastatic bladder cancer The academic analysis data was announced at this conference, let's take a look .
-
"Philippines" long-term vision - Big coffee visits Professor Gou Xin, Liu Jiumin, and Zhang Zheng: exploring the frontier of ASCO-GU, talking about a new era of deep ketone reduction in prostate cancer
Time of Update: 2022-06-17
Professor Liu Jiumin: From the perspective of ASCO-GU, ADT is the basic treatment plan for locally advanced or metastatic prostate cancer, and drug castration is its core treatment method .
-
2022 The results of AACRCG0070 combined with pembrolizumab in the treatment of non-muscle invasive bladder cancer in stage II are encouraging
Time of Update: 2022-06-17
One of the phase II, single-arm studies of CG0070 in combination with pembrolizumab in non-muscle-invasive bladder cancer (NMIBC) patients who did not respond to Bacille Calmette-Guerin (BCG) has published preliminary data, let's take a look .
-
Beware of Pediatric Urinary Tract Infections Caused by "Morganella Morse"
Time of Update: 2022-06-17
However, there have been few studies in children of urinary tract infections (UTIs) caused by Morganella spp .
Ten children with lower urinary tract infection without specific clinical manifestations had normal or mildly elevated white blood cell counts, procalcitonin (PCT) levels, and normal C-reactive protein (CRP) levels .
-
Express 75% of patients maintained complete remission after one year, with positive Phase 2 clinical results of oncolytic virus/PD-1 antibody combination
Time of Update: 2022-06-17
▎WuXi AppTec Content Team Editor Today, CG Oncology announced that the company's oncolytic virus therapy CG0070, in combination with Merck's anti-PD-1 antibody Keytruda, has been approved in a Phase 2 clinical trial for the treatment of non-muscle invasive bladder cancer.
-
Urotropine hippurate is effective in preventing recurrent urinary tract infections
Time of Update: 2022-06-16
In a pragmatic noninferiority trial, UK investigators randomly assigned 240 women with recurrent symptomatic UTIs (average of 7 episodes in the past 1 year) to receive daily low-dose antibiotic prophylaxis Medication (nitrofurantoin, trimethoprim, or cephalexin, as determined by the patient and clinician), and the other group received prophylactic urotropine hippurate (100 mg twice daily) for 12 months .
-
2022 AACR new immune drug MVP-S combination therapy: new hope for patients with advanced bladder cancer
Time of Update: 2022-06-16
Safety, preliminary efficacy, and efficacy of the combination of maveropepimut-S (MVP-S), intermittent low-dose cyclophosphamide, and pembrolizumab in patients with advanced, metastatic bladder cancer The academic analysis data was announced at this conference, let's take a look .
-
Practical sharing of anterior gland cases - similar in shape but different in quality, abiraterone has achieved remarkable benefits with the classics of original research
Time of Update: 2022-06-16
Figure 7 Recommendations of CSCO guidelines for the diagnosis and treatment of post-metastatic prostate cancer In the above two cases, the original abiraterone acetate can quickly relieve the patient's PSA level .
